COVID Vaccine in Pregnancy Protects Newborns, Study Confirms

The antibodies passed from a mother to her baby during pregnancy offer a window of protection against COVID-19, lasting roughly five months, according to a new study published Friday in the journal Pediatrics. The findings, based on data from over 140,000 infants, reinforce current recommendations from the American College of Obstetricians and Gynecologists (ACOG) for COVID-19 vaccination during pregnancy, particularly as infants under six months remain ineligible for direct vaccination.

The study arrives at a time of evolving understanding of COVID-19’s impact on both pregnant individuals and their newborns. While initial concerns centered on the risk of severe illness in pregnant people – a risk confirmed by research showing increased likelihood of complications like preterm birth and preeclampsia – the question of how to best protect the most vulnerable infants remained. The research highlights a crucial benefit of maternal vaccination: a temporary, but significant, shield for babies in their earliest months.

How Maternal Antibodies Offer Protection

The mechanism is well-established: when a pregnant person receives a COVID-19 vaccine, their body produces antibodies that can cross the placenta, providing passive immunity to the developing fetus. This means the baby is born with some level of protection against the virus. Dr. Kevin Ault, a professor of obstetrics and gynecology at Western Michigan University Homer Stryker M.D. School of Medicine, explained that “one of the benefits of COVID vaccination during pregnancy is the passage of antibodies to the newborn, and then that protects the newborn against COVID.”

However, this protection isn’t indefinite. The new study demonstrates that the level of antibodies wanes over time, with the benefit diminishing after approximately five months. This timeframe underscores the importance of continued vigilance and preventative measures, especially as infants approach six months of age and become eligible for vaccination.

Study Details and Scope

Researchers analyzed data from over 146,000 births between March 2020 and December 2023. Approximately one in four mothers in the study received a COVID-19 vaccine during pregnancy. The study tracked infant hospitalizations for COVID-19, finding that babies exposed to the vaccine *in utero* were about half as likely to be hospitalized with COVID-19 in their first two months of life compared to those not exposed. This protective effect decreased to 24% between three and five months, and was no longer significant after six months.

Importantly, the study also investigated whether maternal vaccination influenced the risk of *other* infections in infants. Contrary to claims made by some, including Robert F. Kennedy Jr.’s appointee to a vaccine policy committee, the research found no evidence that vaccination increased the risk of other infections. This finding directly challenges assertions of “immune dysregulation” resulting from the vaccine, which have been circulating without scientific backing. A recent federal judge’s ruling also invalidated the appointments of Kennedy’s committee members, citing procedural irregularities.

Contextualizing the Risk

The study’s findings are particularly relevant given the continued vulnerability of infants to severe COVID-19. Data from September 2024 showed that infants under six months of age experience hospitalization rates comparable to those aged 65 to 74 – a demographic known to be at high risk. Approximately one in five infants hospitalized with COVID-19 required ICU admission.

While the study provides strong evidence of the benefits of maternal vaccination, researchers acknowledge certain limitations. The study was conducted in Norway, where healthcare is universally accessible, which may influence health-seeking behaviors. Researchers accounted for this by focusing their analysis on women with similar healthcare utilization patterns, but the potential for residual confounding remains. The study focused on hospitalizations; it did not assess the impact of maternal vaccination on milder cases of COVID-19 in infants.

What This Means for Pregnant Individuals and Families

The research reinforces the existing guidance from ACOG and other medical organizations recommending COVID-19 vaccination during pregnancy. The benefits – protecting both the pregnant person and providing temporary immunity to the newborn – outweigh the risks. However, it’s crucial to remember that this protection is not permanent.

As Dr. Thomas Nguyen, a pediatrician in northeast Ohio, notes, the study “confirms that we were correct in making those recommendations.” He emphasizes that the study’s large sample size, facilitated by Norway’s healthcare system, adds to its credibility.

Looking Ahead: Ongoing Surveillance and Research

Public health officials continue to monitor COVID-19 trends and assess the effectiveness of vaccines. Ongoing surveillance efforts are crucial for identifying new variants and understanding their impact on different populations, including pregnant individuals and infants. Further research is needed to investigate the long-term effects of maternal COVID-19 vaccination on infant development, as suggested by recent findings linking maternal COVID-19 infection to an elevated risk of neurodevelopmental disorders in children by age three.

For now, the message remains clear: vaccination during pregnancy is a safe and effective way to protect both mother and baby from the immediate threat of COVID-19. Families should continue to follow the latest guidance from public health authorities and consult with their healthcare providers for personalized advice.